A Phase 2 interventional study of VIR-2218 and VIR-3434 in Hepatitis B, Chronic, sponsored by Vir Biotechnology, Inc.. Completed at 37 sites in 12 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Vir Biotechnology, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Hepatitis B, Chronic with a site in Taiwan — 3 open to participants now, 10 under way, 1 of them phase 3. Hepatitis B, Chronic · Taiwan.
Among the 99 studies in Hepatitis B, Chronic with a site in Taiwan, this one is the 24th largest by enrollment of the 88 interventional ones that give a count, is one of 7 that started in 2021, is one of 26 in phase 2, and was the 77th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 99 studies in Hepatitis B, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Taiwan, Australia, China and 4 more countries
Ages 18–65
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 20+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–70
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 30 · Phase 3 16 · Phase 4 22
First in 2002; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 120 across the 88 interventional studies, 335 across the 10 observational. Of the 70 that completed or were terminated, 39 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 99 have an industry lead sponsor. The 10 most frequent:
Vir Biotechnology, Inc. is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Vir Biotechnology, Inc. has 5 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis B, Chronic with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT05956379National Taiwan University HospitalChronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention. | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in Hepatitis B, Chronic with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks
Drug: VIR-2218 · Drug: VIR-3434
Participants will receive multiple doses of VIR-3434 for 44 weeks
Drug: VIR-3434
Participants will receive multiple doses of VIR-3434 for 20 weeks
Drug: VIR-3434
Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks
Drug: VIR-2218 · Drug: VIR-3434 · Drug: PEG-IFNα
Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks
Drug: VIR-2218 · Drug: VIR-3434 · Drug: PEG-IFNα
Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks
Drug: VIR-3434 · Drug: PEG-IFNα
Proportion of participants with treatment-emergent adverse events (TEAEs)
Time frame: Up to 72 weeks
Proportion of participants with serious adverse events (SAEs)
Time frame: Up to 72 weeks
Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment
Time frame: Up to 48 weeks
Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment
Time frame: Up to 72 weeks
Absolute serum HBsAg and change from baseline across all timepoints in the study
Time frame: Up to 110 weeks
Nadir and maximum reduction of serum HBsAg from baseline
Time frame: Up to 110 weeks
Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)
Time frame: Up to 110 weeks
For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint
Time frame: Up to 110 weeks
For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion
Time frame: Up to 110 weeks
Cmax
Time frame: Up to 110 weeks
AUClast
Time frame: Up to 110 weeks
t1/2
Time frame: Up to 110 weeks
CL/F
Time frame: Up to 110 weeks
Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434
Time frame: Up to 110 weeks
Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation
Time frame: Up to 60 weeks
Proportion of participants meeting criteria for NRTI retreatment
Time frame: Up to 110 weeks
Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs
Time frame: Up to 110 weeks
Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment
Time frame: Up to 48 weeks
Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment
48 weeks treatment + 24 weeks post-end of treatment
Time frame: Up to 72 weeks
Proportion of participants with anti-HBs seroconversion
Time frame: Up to 110 weeks
Time to achieve nadir of serum HBsAg
Time frame: Up to 110 weeks
Time to achieve serum HBsAg loss
Time frame: Up to 110 weeks
Plan to share: No
Ran from Jul 2021 to primary completion in Mar 2026, 56 months.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 56 months is above that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tobevibart